1.	Phase II Study of Vaccine Therapy Comprising EP-2101 Emulsified in Montanide ISA-51 in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EPIMMUNE-EP2101-201, MCMRC-0461, NCT00104780
2.	Phase I Study of Adjuvant EP-2101 Peptide Vaccine in Patients With Stage IIB or IIIA Non-Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EPIMMUNE-EP2101-101, USO-02081, UCLA-030106
3.	An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EP2101-102, NCT00054912